查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球血液癌症治疗市场研究报告（2026版）
市场调查报告书
商品编码
2000369

全球血液癌症治疗市场研究报告（2026版）

Global Blood Cancer Drugs Market Research Report 2026
出版日期: | 出版商: QYResearch | 英文 132 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年全球血液癌症治疗市场价值为 746.05 亿美元，预计从 2026 年到 2032 年将以 9.21% 的复合年增长率增长，到 2032 年达到 1388.11 亿美元。

预计北美血液癌症治疗市场将从 2025 年的 366.21 亿美元成长到 2032 年的 626.71 亿美元，2026 年至 2032 年的复合年增长率为 7.79%。

预计亚太地区血液肿瘤治疗市场将从 2025 年的 186.66 亿美元成长到 2032 年的 419.52 亿美元，2026 年至 2032 年的复合年增长率为 12.35%。

全球领先的血液癌症治疗公司包括百时美施贵宝、强生、艾伯维、诺华、罗氏、安进、武田製药、辉瑞、Astra Zeneca和吉利德科学。截至2025年，全球前三大供应商的销售额约占49.54%。

本报告透过定量和定性分析，全面概述了全球血液肿瘤治疗市场，旨在帮助读者制定成长策略、评估竞争格局、了解自身当前市场地位，并就血液肿瘤治疗做出明智的商业决策。报告以2025年为基准年，以收入（百万美元）为基础，呈现了血液肿瘤治疗市场的规模、估算和预测，并涵盖了2021年至2032年的历史数据和预测数据。

本报告对全球血液癌症治疗市场进行了全面的细分，并按类型、疾病和公司列出了各区域的市场规模。为了提供更深入的见解，报告分析了竞争格局、主要竞争对手及其各自的市场排名，并探讨了技术趋势和新产品开发。

本报告向血液癌症治疗製造商、新参与企业以及整个行业价值链中的公司提供按公司、类型、疾病和地区分類的整体市场及其细分市场的销售额、销售量和平均价格资讯。

市场区隔

公司

  • Johnson &Johnson
  • Bristol-Myers Squibb
  • Novartis
  • AbbVie
  • Roche
  • BeiGene
  • Amgen
  • AstraZeneca
  • Incyte Corporation
  • Takeda
  • Gilead Sciences
  • Pfizer
  • Sanofi
  • Astellas Pharma

按类型分類的细分市场

  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 其他的

疾病特异性片段

  • 白血病
  • 淋巴瘤
  • 多发性骨髓瘤

区域板块

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 南美洲
    • 巴西
  • 中东和非洲
    • 中东
    • 其他欧洲国家、南美洲、巴西、中东和非洲

The global Blood Cancer Drugs market was valued at US$ 74605 million in 2025 and is anticipated to reach US$ 138811 million by 2032, at a CAGR of 9.21% from 2026 to 2032.

The North American market for Blood Cancer Drugs is projected to increase from US$ 36621 million in 2025 to US$ 62671 million by 2032, at a CAGR of 7.79% over 2026-2032.

The Asia-Pacific market for Blood Cancer Drugs is projected to rise from US$ 18666 million in 2025 to US$ 41952 million by 2032, at a CAGR of 12.35% over 2026-2032.

Major global companies of Blood Cancer Drugs include Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer, AstraZeneca, Gilead Sciences, etc. In 2025, the world's top three vendors accounted for approximately 49.54% of revenue.

This report delivers a comprehensive overview of the global Blood Cancer Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Blood Cancer Drugs. The Blood Cancer Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021-2032.

The report segments the global Blood Cancer Drugs market comprehensively. Regional market sizes by Type, by Disease, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Blood Cancer Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Disease, and by region.

Market Segmentation

By Company

  • Johnson & Johnson
  • Bristol-Myers Squibb
  • Novartis
  • AbbVie
  • Roche
  • BeiGene
  • Amgen
  • AstraZeneca
  • Incyte Corporation
  • Takeda
  • Gilead Sciences
  • Pfizer
  • Sanofi
  • Astellas Pharma

Segment by Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Other

Segment by Disease

  • Leukemia
  • Lymphoma
  • Multiple Myeloma

Segment by Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
  • Middle East & Africa
    • Middle East
    • Africa

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Disease, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.

Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.

Chapter 3: Provides a detailed view of the competitive landscape for Blood Cancer Drugs companies, covering revenue share, development plans, and mergers and acquisitions.

Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 5: Analyzes segments by Disease, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 6-10: Regional deep dives (North America, Europe, Asia Pacific, South America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.

Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.

Chapter 12: Key findings and conclusions of the report.

Table of Contents

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Blood Cancer Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
    • 1.2.2 Chemotherapy
    • 1.2.3 Targeted Therapy
    • 1.2.4 Immunotherapy
  • 1.3 Market by Disease
    • 1.3.1 Global Blood Cancer Drugs Market Growth by Disease: 2021 vs 2025 vs 2032
    • 1.3.2 Leukemia
    • 1.3.3 Lymphoma
    • 1.3.4 Multiple Myeloma
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Blood Cancer Drugs Market Perspective (2021-2032)
  • 2.2 Global Blood Cancer Drugs Growth Trends by Region
    • 2.2.1 Global Blood Cancer Drugs Market Size by Region: 2021 vs 2025 vs 2032
    • 2.2.2 Blood Cancer Drugs Historic Market Size by Region (2021-2026)
    • 2.2.3 Blood Cancer Drugs Forecasted Market Size by Region (2027-2032)
  • 2.3 Blood Cancer Drugs Market Dynamics
    • 2.3.1 Blood Cancer Drugs Industry Trends
    • 2.3.2 Blood Cancer Drugs Market Drivers
    • 2.3.3 Blood Cancer Drugs Market Challenges
    • 2.3.4 Blood Cancer Drugs Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Blood Cancer Drugs Players by Revenue
    • 3.1.1 Global Top Blood Cancer Drugs Players by Revenue (2021-2026)
    • 3.1.2 Global Blood Cancer Drugs Revenue Market Share by Players (2021-2026)
  • 3.2 Global Top Blood Cancer Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
  • 3.3 Global Key Players Ranking by Blood Cancer Drugs Revenue
  • 3.4 Global Blood Cancer Drugs Market Concentration Ratio
    • 3.4.1 Global Blood Cancer Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Blood Cancer Drugs Revenue in 2025
  • 3.5 Global Key Players of Blood Cancer Drugs Head Offices and Areas Served
  • 3.6 Global Key Players of Blood Cancer Drugs, Products
  • 3.7 Global Key Players of Blood Cancer Drugs, Founded Date
  • 3.8 Mergers and Acquisitions, Expansion Plans

4 Blood Cancer Drugs Breakdown Data by Type

  • 4.1 Global Blood Cancer Drugs Historic Market Size by Type (2021-2026)
  • 4.2 Global Blood Cancer Drugs Forecasted Market Size by Type (2027-2032)

5 Blood Cancer Drugs Breakdown Data by Disease

  • 5.1 Global Blood Cancer Drugs Historic Market Size by Disease (2021-2026)
  • 5.2 Global Blood Cancer Drugs Forecasted Market Size by Disease (2027-2032)

6 North America

  • 6.1 North America Blood Cancer Drugs Market Size (2021-2032)
  • 6.2 North America Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
  • 6.3 North America Blood Cancer Drugs Market Size by Country (2021-2026)
  • 6.4 North America Blood Cancer Drugs Market Size by Country (2027-2032)
  • 6.5 United States
  • 6.6 Canada
  • 6.7 Mexico

7 Europe

  • 7.1 Europe Blood Cancer Drugs Market Size (2021-2032)
  • 7.2 Europe Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
  • 7.3 Europe Blood Cancer Drugs Market Size by Country (2021-2026)
  • 7.4 Europe Blood Cancer Drugs Market Size by Country (2027-2032)
  • 7.5 Germany
  • 7.6 France
  • 7.7 U.K.
  • 7.8 Italy
  • 7.9 Russia

8 Asia-Pacific

  • 8.1 Asia-Pacific Blood Cancer Drugs Market Size (2021-2032)
  • 8.2 Asia-Pacific Blood Cancer Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032
  • 8.3 Asia-Pacific Blood Cancer Drugs Market Size by Region (2021-2026)
  • 8.4 Asia-Pacific Blood Cancer Drugs Market Size by Region (2027-2032)
  • 8.5 China
  • 8.6 Japan
  • 8.7 South Korea
  • 8.8 Southeast Asia
  • 8.9 India

9 South America

  • 9.1 South America Blood Cancer Drugs Market Size (2021-2032)
  • 9.2 South America Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
  • 9.3 South America Blood Cancer Drugs Market Size by Country (2021-2026)
  • 9.4 South America Blood Cancer Drugs Market Size by Country (2027-2032)
  • 9.5 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Blood Cancer Drugs Market Size (2021-2032)
  • 10.2 Middle East & Africa Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
  • 10.3 Middle East & Africa Blood Cancer Drugs Market Size by Country (2021-2026)
  • 10.4 Middle East & Africa Blood Cancer Drugs Market Size by Country (2027-2032)
  • 10.5 Middle East
  • 10.6 Africa

11 Key Players Profiles

  • 11.1 Bristol-Myers Squibb
    • 11.1.1 Bristol-Myers Squibb Company Details
    • 11.1.2 Bristol-Myers Squibb Business Overview
    • 11.1.3 Bristol-Myers Squibb Blood Cancer Drugs Introduction
    • 11.1.4 Bristol-Myers Squibb Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.1.5 Bristol-Myers Squibb Recent Development
  • 11.2 Johnson & Johnson
    • 11.2.1 Johnson & Johnson Company Details
    • 11.2.2 Johnson & Johnson Business Overview
    • 11.2.3 Johnson & Johnson Blood Cancer Drugs Introduction
    • 11.2.4 Johnson & Johnson Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.2.5 Johnson & Johnson Recent Development
  • 11.3 AbbVie
    • 11.3.1 AbbVie Company Details
    • 11.3.2 AbbVie Business Overview
    • 11.3.3 AbbVie Blood Cancer Drugs Introduction
    • 11.3.4 AbbVie Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.3.5 AbbVie Recent Development
  • 11.4 Novartis
    • 11.4.1 Novartis Company Details
    • 11.4.2 Novartis Business Overview
    • 11.4.3 Novartis Blood Cancer Drugs Introduction
    • 11.4.4 Novartis Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.4.5 Novartis Recent Development
  • 11.5 Roche
    • 11.5.1 Roche Company Details
    • 11.5.2 Roche Business Overview
    • 11.5.3 Roche Blood Cancer Drugs Introduction
    • 11.5.4 Roche Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.5.5 Roche Recent Development
  • 11.6 Amgen
    • 11.6.1 Amgen Company Details
    • 11.6.2 Amgen Business Overview
    • 11.6.3 Amgen Blood Cancer Drugs Introduction
    • 11.6.4 Amgen Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.6.5 Amgen Recent Development
  • 11.7 Takeda
    • 11.7.1 Takeda Company Details
    • 11.7.2 Takeda Business Overview
    • 11.7.3 Takeda Blood Cancer Drugs Introduction
    • 11.7.4 Takeda Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.7.5 Takeda Recent Development
  • 11.8 Pfizer
    • 11.8.1 Pfizer Company Details
    • 11.8.2 Pfizer Business Overview
    • 11.8.3 Pfizer Blood Cancer Drugs Introduction
    • 11.8.4 Pfizer Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.9 AstraZeneca
    • 11.9.1 AstraZeneca Company Details
    • 11.9.2 AstraZeneca Business Overview
    • 11.9.3 AstraZeneca Blood Cancer Drugs Introduction
    • 11.9.4 AstraZeneca Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.9.5 AstraZeneca Recent Development
  • 11.10 Gilead Sciences
    • 11.10.1 Gilead Sciences Company Details
    • 11.10.2 Gilead Sciences Business Overview
    • 11.10.3 Gilead Sciences Blood Cancer Drugs Introduction
    • 11.10.4 Gilead Sciences Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.10.5 Gilead Sciences Recent Development
  • 11.11 Sanofi
    • 11.11.1 Sanofi Company Details
    • 11.11.2 Sanofi Business Overview
    • 11.11.3 Sanofi Blood Cancer Drugs Introduction
    • 11.11.4 Sanofi Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.12 Incyte Corporation
    • 11.12.1 Incyte Corporation Company Details
    • 11.12.2 Incyte Corporation Business Overview
    • 11.12.3 Incyte Corporation Blood Cancer Drugs Introduction
    • 11.12.4 Incyte Corporation Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.13 BeiGene
    • 11.13.1 BeiGene Company Details
    • 11.13.2 BeiGene Business Overview
    • 11.13.3 BeiGene Blood Cancer Drugs Introduction
    • 11.13.4 BeiGene Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.13.5 BeiGene Recent Development
  • 11.14 Astellas Pharma
    • 11.14.1 Astellas Pharma Company Details
    • 11.14.2 Astellas Pharma Business Overview
    • 11.14.3 Astellas Pharma Blood Cancer Drugs Introduction
    • 11.14.4 Astellas Pharma Revenue in Blood Cancer Drugs Business (2021-2026)
    • 11.14.5 Astellas Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Author Details
  • 13.3 Disclaimer
  • Table 1. Global Blood Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
  • Table 2. Global Blood Cancer Drugs Market Size Growth by Disease (US$ Million): 2021 vs 2025 vs 2032
  • Table 3. Global Blood Cancer Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
  • Table 4. Global Blood Cancer Drugs Market Size by Region (US$ Million), 2021-2026
  • Table 5. Global Blood Cancer Drugs Market Share by Region (2021-2026)
  • Table 6. Global Blood Cancer Drugs Forecasted Market Size by Region (US$ Million), 2027-2032
  • Table 7. Global Blood Cancer Drugs Market Share by Region (2027-2032)
  • Table 8. Blood Cancer Drugs Market Trends
  • Table 9. Blood Cancer Drugs Market Drivers
  • Table 10. Blood Cancer Drugs Market Challenges
  • Table 11. Blood Cancer Drugs Market Restraints
  • Table 12. Global Blood Cancer Drugs Revenue by Players (US$ Million), 2021-2026
  • Table 13. Global Blood Cancer Drugs Market Share by Players (2021-2026)
  • Table 14. Global Top Blood Cancer Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Blood Cancer Drugs Revenue, 2025
  • Table 15. Ranking of Global Top Blood Cancer Drugs Companies by Revenue (US$ Million) in 2025
  • Table 16. Global 5 Largest Players Market Share by Blood Cancer Drugs Revenue (CR5 and HHI), 2021-2026
  • Table 17. Global Key Players of Blood Cancer Drugs, Headquarters and Area Served
  • Table 18. Global Key Players of Blood Cancer Drugs, Products
  • Table 19. Global Key Players of Blood Cancer Drugs, Founded Date
  • Table 20. Mergers and Acquisitions, Expansion Plans
  • Table 21. Global Blood Cancer Drugs Market Size by Type (US$ Million), 2021-2026
  • Table 22. Global Blood Cancer Drugs Revenue Market Share by Type (2021-2026)
  • Table 23. Global Blood Cancer Drugs Forecasted Market Size by Type (US$ Million), 2027-2032
  • Table 24. Global Blood Cancer Drugs Revenue Market Share by Type (2027-2032)
  • Table 25. Global Blood Cancer Drugs Market Size by Disease (US$ Million), 2021-2026
  • Table 26. Global Blood Cancer Drugs Revenue Market Share by Disease (2021-2026)
  • Table 27. Global Blood Cancer Drugs Forecasted Market Size by Disease (US$ Million), 2027-2032
  • Table 28. Global Blood Cancer Drugs Revenue Market Share by Disease (2027-2032)
  • Table 29. North America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
  • Table 30. North America Blood Cancer Drugs Market Size by Country (US$ Million), 2021-2026
  • Table 31. North America Blood Cancer Drugs Market Size by Country (US$ Million), 2027-2032
  • Table 32. Europe Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
  • Table 33. Europe Blood Cancer Drugs Market Size by Country (US$ Million), 2021-2026
  • Table 34. Europe Blood Cancer Drugs Market Size by Country (US$ Million), 2027-2032
  • Table 35. Asia-Pacific Blood Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
  • Table 36. Asia-Pacific Blood Cancer Drugs Market Size by Region (US$ Million), 2021-2026
  • Table 37. Asia-Pacific Blood Cancer Drugs Market Size by Region (US$ Million), 2027-2032
  • Table 38. South America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
  • Table 39. South America Blood Cancer Drugs Market Size by Country (US$ Million), 2021-2026
  • Table 40. South America Blood Cancer Drugs Market Size by Country (US$ Million), 2027-2032
  • Table 41. Middle East & Africa Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
  • Table 42. Middle East & Africa Blood Cancer Drugs Market Size by Country (US$ Million), 2021-2026
  • Table 43. Middle East & Africa Blood Cancer Drugs Market Size by Country (US$ Million), 2027-2032
  • Table 44. Bristol-Myers Squibb Company Details
  • Table 45. Bristol-Myers Squibb Business Overview
  • Table 46. Bristol-Myers Squibb Blood Cancer Drugs Product
  • Table 47. Bristol-Myers Squibb Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 48. Bristol-Myers Squibb Recent Development
  • Table 49. Johnson & Johnson Company Details
  • Table 50. Johnson & Johnson Business Overview
  • Table 51. Johnson & Johnson Blood Cancer Drugs Product
  • Table 52. Johnson & Johnson Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 53. Johnson & Johnson Recent Development
  • Table 54. AbbVie Company Details
  • Table 55. AbbVie Business Overview
  • Table 56. AbbVie Blood Cancer Drugs Product
  • Table 57. AbbVie Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 58. AbbVie Recent Development
  • Table 59. Novartis Company Details
  • Table 60. Novartis Business Overview
  • Table 61. Novartis Blood Cancer Drugs Product
  • Table 62. Novartis Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 63. Novartis Recent Development
  • Table 64. Roche Company Details
  • Table 65. Roche Business Overview
  • Table 66. Roche Blood Cancer Drugs Product
  • Table 67. Roche Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 68. Roche Recent Development
  • Table 69. Amgen Company Details
  • Table 70. Amgen Business Overview
  • Table 71. Amgen Blood Cancer Drugs Product
  • Table 72. Amgen Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 73. Amgen Recent Development
  • Table 74. Takeda Company Details
  • Table 75. Takeda Business Overview
  • Table 76. Takeda Blood Cancer Drugs Product
  • Table 77. Takeda Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 78. Takeda Recent Development
  • Table 79. Pfizer Company Details
  • Table 80. Pfizer Business Overview
  • Table 81. Pfizer Blood Cancer Drugs Product
  • Table 82. Pfizer Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 83. AstraZeneca Company Details
  • Table 84. AstraZeneca Business Overview
  • Table 85. AstraZeneca Blood Cancer Drugs Product
  • Table 86. AstraZeneca Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 87. AstraZeneca Recent Development
  • Table 88. Gilead Sciences Company Details
  • Table 89. Gilead Sciences Business Overview
  • Table 90. Gilead Sciences Blood Cancer Drugs Product
  • Table 91. Gilead Sciences Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 92. Gilead Sciences Recent Development
  • Table 93. Sanofi Company Details
  • Table 94. Sanofi Business Overview
  • Table 95. Sanofi Blood Cancer Drugs Product
  • Table 96. Sanofi Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 97. Incyte Corporation Company Details
  • Table 98. Incyte Corporation Business Overview
  • Table 99. Incyte Corporation Blood Cancer Drugs Product
  • Table 100. Incyte Corporation Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 101. BeiGene Company Details
  • Table 102. BeiGene Business Overview
  • Table 103. BeiGene Blood Cancer Drugs Product
  • Table 104. BeiGene Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 105. BeiGene Recent Development
  • Table 106. Astellas Pharma Company Details
  • Table 107. Astellas Pharma Business Overview
  • Table 108. Astellas Pharma Blood Cancer Drugs Product
  • Table 109. Astellas Pharma Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
  • Table 110. Astellas Pharma Recent Development
  • Table 111. Research Programs/Design for This Report
  • Table 112. Key Data Information from Secondary Sources
  • Table 113. Key Data Information from Primary Sources
  • Table 114. Authors List of This Report

List of Figures

  • Figure 1. Blood Cancer Drugs Picture
  • Figure 2. Global Blood Cancer Drugs Market Size Comparison by Type (US$ Million), 2021-2032
  • Figure 3. Global Blood Cancer Drugs Market Share by Type: 2025
  • Figure 4. Global Blood Cancer Drugs Market Share by Type: 2032
  • Figure 5. Chemotherapy Features
  • Figure 6. Targeted Therapy Features
  • Figure 7. Immunotherapy Features
  • Figure 8. Global Blood Cancer Drugs Market Size by Disease (US$ Million), 2021-2032
  • Figure 9. Global Blood Cancer Drugs Market Share by Disease: 2025
  • Figure 10. Global Blood Cancer Drugs Market Share by Disease: 2032
  • Figure 11. Leukemia Case Studies
  • Figure 12. Lymphoma Case Studies
  • Figure 13. Multiple Myeloma Case Studies
  • Figure 14. Blood Cancer Drugs Report Years Considered
  • Figure 15. Global Blood Cancer Drugs Market Size (US$ Million), Year-over-Year: 2021-2032
  • Figure 16. Global Blood Cancer Drugs Market Size, (US$ Million), 2021 vs 2026 vs 2032
  • Figure 17. Global Blood Cancer Drugs Market Share by Region: 2025
  • Figure 18. Global Blood Cancer Drugs Market Share by Region: 2032
  • Figure 19. Global Blood Cancer Drugs Market Share by Players in 2025
  • Figure 20. The Top 5 Players Market Share by Blood Cancer Drugs Revenue in 2025
  • Figure 21. The Top 10 Players Market Share by Blood Cancer Drugs Revenue in 2025
  • Figure 22. North America Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 23. North America Blood Cancer Drugs Market Share by Country (2021-2032)
  • Figure 24. United States Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 25. Canada Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 26. Mexico Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 27. Europe Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 28. Europe Blood Cancer Drugs Market Share by Country (2021-2032)
  • Figure 29. Germany Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 30. France Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 31. U.K. Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 32. Italy Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 33. Russia Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 34. Asia-Pacific Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 35. Asia-Pacific Blood Cancer Drugs Market Share by Region (2021-2032)
  • Figure 36. China Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 37. Japan Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 38. South Korea Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 39. Southeast Asia Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 40. India Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 41. South America Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 42. South America Blood Cancer Drugs Market Share by Country (2021-2032)
  • Figure 43. Brazil Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 44. Middle East & Africa Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 45. Middle East & Africa Blood Cancer Drugs Market Share by Country (2021-2032)
  • Figure 46. Middle East Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 47. Africa Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
  • Figure 48. Bristol-Myers Squibb Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 49. Johnson & Johnson Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 50. AbbVie Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 51. Novartis Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 52. Roche Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 53. Amgen Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 54. Takeda Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 55. Pfizer Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 56. AstraZeneca Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 57. Gilead Sciences Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 58. Sanofi Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 59. Incyte Corporation Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 60. BeiGene Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 61. Astellas Pharma Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
  • Figure 62. Bottom-up and Top-down Approaches for This Report
  • Figure 63. Data Triangulation
  • Figure 64. Key Executives Interviewed